TherapeuticsMD Up 40% After Mixed Q3, Plans To Resubmit NDA For TX-004HR

TherapeuticsMD Inc TXMD shares are trading higher by $1.79 (39.8 percent) at $6.15 in Monday's session.

Before the open, the company reported a mixed Q3 report that beat for EPS but missed for sales by $8.1 million.

Investors appear to be encouraged by the news that the company plans to resubmit NDA for TX-004HR, for women with moderate-to-severs vaginal pain during intercourse.

After a higher, TherapeuticsMD retreated but immediately found support at $5.94 and continued its move higher. The ensuing rally took the stock to $6.85, which marks its highest level since it peaked on Sept. 7 at $7.01. Since reaching that level, it has been drifting back towards the low for the session, but has yet to make one as of 12:40 p.m. EST.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsTechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!